ACO/ARO/AIO-21——卡培他滨为基础放化疗联合IL-1受体拮抗剂阿那白滞素治疗直肠癌患者的I期试验:德国直肠癌研究组
ACO/ARO/AIO-21是一项研究者发起的前瞻性开放标签I期药物再利用试验,评估卡培他滨联用固定剂量IL-1受体拮抗剂阿那白滞素(100 mg,第-10至30天)时卡培他滨的最大耐受剂量。卡培他滨采用3+3剂量递增设计(500、650、825 mg/m2每日两次),同步标准术前放疗(45 Gy/25次后9 Gy/5次加强),主要终点为卡培他滨的最大耐受剂量。
要点
- I期试验评估卡培他滨联合阿那白滞素(100 mg,第-10至30天)同步术前放疗的最大耐受剂量。
- 卡培他滨3+3剂量递增为500、650、825 mg/m2每日两次,第1至30天给药。
- 放疗为45 Gy/25次后9 Gy/5次加强,放化疗结束后10周评估疗效。
核心结论
- 基于大量临床前研究,该I期试验将评估IL-1受体拮抗剂阿那白滞素能否与氟尿嘧啶类放化疗安全联合用于直肠癌。
- 试验将进一步探索IL-1抑制克服治疗抵抗和提高缓解率的潜力。
- 综合性转化研究计划可能有助于将结果转化为随机II期试验。
研究设计与样本
- ACO/ARO/AIO-21为研究者发起、前瞻性、开放标签的I期药物再利用试验。
- 试验评估卡培他滨联用固定剂量阿那白滞素(100 mg,第-10至30天)同步标准术前放疗时的最大耐受剂量。
- 卡培他滨采用3+3剂量递增设计:500 mg/m2每日两次、650 mg/m2每日两次、825 mg/m2每日两次,第1至30天给药。
- 标准术前放疗为45 Gy分25次后9 Gy分5次加强。
- 主要终点为卡培他滨的最大耐受剂量。
关键数值与推荐
- 放化疗结束后10周进行疗效评估,包括直肠指检、内镜和盆腔磁共振成像。
- 达到临床完全缓解的患者接受原发非手术治疗。
- 未达到临床完全缓解者立即行全直肠系膜切除术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and survival, remains a major challenge. Our group has recently unraveled a critical role of interleukin-1α (IL-1α) signaling in activating inflammatory cancer-associated fibroblasts (iCAFs) and mediating radiation-induced senescence, extracellular matrix (ECM) accumulation, and ultimately therapy resistance. We here summarize the recently initiated ACO/ARO/AIO-21 phase I trial, testing the IL-1 receptor antagonist (IL-1 RA) anakinra in combination with fluoropyrimidine-based chemoradiotherapy (CRT) for advanced rectal cancer. METHODS/DESIGN: The ACO/ARO/AIO-21 is an investigator-driven, prospective, open-labeled phase I drug-repurposing trial assessing the maximum tolerated dose (MTD) of capecitabine administered concurrently to standard preoperative radiotherapy (45 Gy in 25 fractions followed by 9 Gy boost in 5 fractions) in combination with fixed doses of the IL1-RA anakinra (100 mg, days -10 to 30). Capecitabine will be administered using a 3 + 3 dose-escalation design (500 mg/m2 bid; 650 mg/m2 bid; 825 mg/m2 bid, respectively) from day 1 to day 30. Response assessment including digital rectal examination (DRE), endoscopy and pelvic magnetic resonance imaging (MRI) is scheduled 10 weeks after completion of CRT. For patients achieving clinical complete response (cCR), primary non-operative management is provided. In case of non-cCR immediate total mesorectal excision (TME) will be performed. Primary endpoint of this phase I trial is the MTD of capecitabine. DISCUSSION: Based on extensive preclinical research, the ACO/ARO/AIO-21 phase I trial will assess whether the IL-1RA anakinra can be safely combined with fluoropyrimidine-based CRT in rectal cancer. It will further explore the potential of IL-1 inhibition to overcome therapy resistance and improve response rates. A comprehensive translational research program will expand our understanding from a clinical perspective and may help translate the results into a randomized phase II trial.
引用
- Fleischmann M, Diefenhardt M, Nicolas AM, et al. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clin Transl Radiat Oncol. 2022. PMID: 35449546. doi:10.1016/j.ctro.2022.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。